SCHEMBL12599208

SCHEMBL12599208

Cc1ccc(C(=O)N(C)C)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ HPGD P15428 2/20 0.49
▸ SLC6A2 P23975 3/20 0.47
▸ SLC6A4 P31645 3/20 0.47
▸ SLC6A3 Q01959 3/20 0.47
▸ CHRNA1 P02708 1/20 0.47
▸ CHRNG P07510 1/20 0.47
▸ CHRNB1 P11230 1/20 0.47
▸ CHRNB2 P17787 1/20 0.47
▸ CHRNB4 P30926 1/20 0.47
▸ CHRNA3 P32297 1/20 0.47
▸ CHRNA4 P43681 1/20 0.47
▸ CHRND Q07001 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ MAPK11 Q15759 1/20 0.45
▸ HSP90AA1 P07900 2/20 0.45
▸ HSP90AB1 P08238 2/20 0.45
▸ KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8988251 0.82 MLYCD (0.45) NPC1RAB9AHPGDSLC6A2SLC6A4
SCHEMBL12051807 0.82 SMN1; SMN2 (0.52) NPC1RAB9AHPGDALDH1A1SMN1; SMN2
SCHEMBL29421591 0.81 SLC6A2 (0.43) HPGDSLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL15709079 0.81 SLC6A2 (0.43) HPGDSLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL355700 0.81 HSP90AA1 (0.67) HPGDALDH1A1SMN1; SMN2HSP90AA1HSP90AB1
SCHEMBL3787476 0.81 ALDH1A1 (0.51) NPC1RAB9AHPGDSLC6A2SLC6A4
SCHEMBL9686186 0.80 HSP90AA1 (0.71) HPGDSLC6A2SLC6A4SLC6A3CHRNA1
SCHEMBL2924706 0.79 HPGD (0.54) NPC1RAB9AHPGDSLC6A2SLC6A4
SCHEMBL15709090 0.79 ALDH1A1 (0.50) NPC1RAB9AHPGDSLC6A2SLC6A4
SCHEMBL357230 0.79 ALDH1A1 (0.49) HPGDSLC6A2SLC6A4SLC6A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022118966-A1 AGENT FOR PROMOTING NUCLEIC ACID MOLECULE UPTAKE INTO CELLS, PHARMACEUTICAL COMPOSITION, AND NOVEL COMPOUND 国立大学法人京都大学 2022-06-09 — — WO disclosed
EP-2421871-B1 THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INT (DE) 2015-09-16 — — EP disclosed
US-8288379-B2 Thia-triaza-cyclopentazulenes BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-16 — — US disclosed
US-20110112087-A1 Thia-triaza-cyclopentazulenes BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112087-A1 Thia-triaza-cyclopentazulenes CCNA1, MKI67, CCNT1 NPC1 686/4885RAB9A 1011/4885HPGD 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback